Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

Authors: Natasha B. Leighl, Matthew D. Hellmann, Rina Hui, Enric Carcereny, Enriqueta Felip, Myung‐Ju Ahn, Joseph P. Eder, Ani Sarkis Balmanoukian, Charu Aggarwal, Leora Horn, Amita Patnaik, Matthew A. Gubens, Suresh S. Ramalingam, Gregory M. Lubiniecki, Jin Zhang, Bilal Piperdi, Edward B. Garon - The Lancet 2019 cited by 182